-
公开(公告)号：US20050064008A1
公开(公告)日：2005-03-24
申请号：US10664601
申请日：2003-09-18
CPC分类号： A61K9/0024 , A61K9/0034 , A61K9/0092 , A61K9/1652 , A61K9/204 , A61K9/205 , A61K9/2054 , A61K45/06
摘要： An injectable or insertable dosage form comprising a biodisintegrable binder and an ablation agent in a concentration effective to cause tissue necrosis. The injectable dosage form is a solid or semi-solid dosage form. Due to the solid or semi-solid nature of the dosage form, retention at the site of injection or insertion is improved, thereby improving delivery efficiency of the ablation agents within the dosage form and/or reducing the nonspecific tissue damage associated with the dosage form.
摘要翻译： 一种可注射或可插入的剂型，其包含生物可分解的粘合剂和消融剂，其浓度有效地引起组织坏死。 可注射剂型是固体或半固体剂型。 由于剂型的固体或半固体性质，提高注射或插入部位的保留性，从而提高剂型内消融剂的输送效率和/或减少与剂型相关的非特异性组织损伤 。
-
公开(公告)号：US20060251581A1
公开(公告)日：2006-11-09
申请号：US11124828
申请日：2005-05-09
申请人： Jon McIntyre , Arthur Madenjian
发明人： Jon McIntyre , Arthur Madenjian
CPC分类号： A61K9/0034 , A61K9/0024 , A61K9/0092 , A61K9/06 , A61K31/045 , A61K31/717 , A61K31/734 , A61K31/74 , A61K31/79 , A61K33/14 , A61K45/06 , A61K49/0002 , A61K2300/00
摘要： Various injectable or insertable uterine fibroid treatment formulations are provided, which comprise a uterine fibroid treatment agent in an amount effective to cause shrinkage or elimination of uterine fibroids. The injectable or insertable formulations are typically solids, semi-solids or high-viscosity fluids. Other aspects of the invention are directed to systems and methods for treatment of uterine fibroids.
摘要翻译： 提供各种可注射或可插入的子宫肌瘤治疗制剂，其包括有效引起子宫肌瘤收缩或消除的量的子宫肌瘤治疗剂。 可注射或可插入的制剂通常为固体，半固体或高粘度流体。 本发明的其它方面涉及用于治疗子宫肌瘤的系统和方法。
-
公开(公告)号：US08012081B2
公开(公告)日：2011-09-06
申请号：US12755099
申请日：2010-04-06
申请人： James Wagner , Arthur Madenjian , Jamie Li
发明人： James Wagner , Arthur Madenjian , Jamie Li
IPC分类号： A61F2/02
CPC分类号： A61F2/0045
摘要： The invention, in one embodiment, is directed to systems and methods for adjusting support to an anatomical location using an expandable chamber.
摘要翻译： 在一个实施例中，本发明涉及用于使用可扩展腔室来调整对解剖位置的支撑的系统和方法。
-
公开(公告)号：US20050064045A1
公开(公告)日：2005-03-24
申请号：US10667151
申请日：2003-09-18
IPC分类号： A61K9/08 , A61K9/10 , A61K31/045 , A61K33/14 , A61K47/02 , A61K47/10 , A61K47/34 , A61K47/38 , A61P13/08
CPC分类号： A61K9/0019 , A61K47/32 , A61K47/36 , A61K47/38
摘要： Sterile injectable formulations, which comprise the following: (a) a ablation agent in an amount effective to cause necrosis of tissue, and (b) a biodisintegrable viscosity adjusting agent in an amount effective to render the formulation highly viscous, (c) an optional imaging contrast agent, (d) an optional therapeutic agent, and (e) an optional liquid selected from water and an organic solvent. Also described are novel prostatic ablation formulations, which comprise a prostatic ablation agent selected from free-radical generating ablation agents, oxidizing ablation agents and tissue fixing ablation agents. Further aspects of the invention relate to methods of treating a variety of diseases and conditions, including benign prostatic hypertrophy, in which above injectable formulations are injected into the tissue of a subject, optionally with the assistance of a non-invasive imaging technique.
摘要翻译： 无菌可注射制剂，其包含以下物质：（a）有效引起组织坏死的量的消融剂，和（b）有效使制剂高度粘稠的量的生物可分解粘度调节剂，（c）任选的 成像造影剂，（d）任选的治疗剂，和（e）选自水和有机溶剂的任选液体。 还描述了新型前列腺消融制剂，其包含选自自由基产生消融剂，氧化消融剂和组织固定消融剂的前列腺消融剂。 本发明的其它方面涉及治疗各种疾病和病症（包括良性前列腺肥大）的方法，其中任选地在非侵入性成像技术的帮助下，上述可注射制剂注射到受试者的组织中。
-
公开(公告)号：US07906125B2
公开(公告)日：2011-03-15
申请号：US10664601
申请日：2003-09-18
CPC分类号： A61K9/0024 , A61K9/0034 , A61K9/0092 , A61K9/1652 , A61K9/204 , A61K9/205 , A61K9/2054 , A61K45/06
摘要： An injectable or insertable dosage form comprising a biodisintegrable binder and an ablation agent in a concentration effective to cause tissue necrosis. The injectable dosage form is a solid or semi-solid dosage form. Due to the solid or semi-solid nature of the dosage form, retention at the site of injection or insertion is improved, thereby improving delivery efficiency of the ablation agents within the dosage form and/or reducing the nonspecific tissue damage associated with the dosage form.
摘要翻译： 一种可注射或可插入的剂型，其包含生物可分解的粘合剂和消融剂，其浓度有效地引起组织坏死。 可注射剂型是固体或半固体剂型。 由于剂型的固体或半固体性质，提高注射或插入部位的保留性，从而提高剂型内消融剂的输送效率和/或减少与剂型相关的非特异性组织损伤 。
-
公开(公告)号：US20050080477A1
公开(公告)日：2005-04-14
申请号：US10951131
申请日：2004-09-27
申请人： Gregory Sydney , Russ Seiber , Arthur Madenjian , Annette Belovi
发明人： Gregory Sydney , Russ Seiber , Arthur Madenjian , Annette Belovi
CPC分类号： A61F2/958 , A61F2002/9583
摘要： A predetermined arrangement of differentially lubricious areas on a balloon catheter for controlling against unexpected movement of a stent carried thereon when in situ in the body.
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.019 秒)
